Inflammatory and cardiac biomarkers in pulmonary arterial hypertension: The prognostic role of IL-34

被引:1
作者
Bolayir, Hasan Ata [1 ]
Karasu, Mehdi [2 ]
Gelen, Mehmet Ali [2 ]
Akin, Yusuf [2 ]
Cecen, Erkan [3 ]
Kucuk, Ugur [4 ]
Bulu, Aykut [5 ]
机构
[1] Malatya Turgut Ozal Universitesi Kardiyoloji ABD, Dept Cardiol, Malatya, Turkiye
[2] Fethi Sekin Sehir Hastanesi, Dept Cardiol, Elazig, Turkiye
[3] Firat Universitesi Tip Fakultesi Hastanesi, Dept Cardiol, Elazig, Turkiye
[4] Canakkale 18 Mart Universitesi Kardiyoloji ABD, Dept Cardiol, Canakkale, Turkiye
[5] Fethi Sekin Sehir Hastanesi, Dept Internal Med, Elazig, Turkiye
来源
HEART & LUNG | 2025年 / 69卷
关键词
Pulmonary arterial hypertension (PAH); IL-34; Inflammation; Biomarkers; Right Ventricular Dysfunction; EXPRESSION; SURVIVAL; CYTOKINE; RECEPTOR;
D O I
10.1016/j.hrtlng.2024.10.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Pulmonary arterial hypertension (PAH) is characterized by increased pulmonary artery pressure with significant morbidity and mortality. Inflammatory processes are crucial in PAH pathogenesis, with inflammatory cells and mediators present early in disease progression. IL-34 involvement in inflammatory pathways suggests that IL-34 could be an important player in the progression of PAH, influencing both pulmonary pressures and vascular changes. Objective: The purpose of this study was to investigate the correlation between IL-34 levels and pulmonary arterial hypertension (PAH), aiming to enhance the understanding of the molecular mechanisms underlying PAH and explore IL-34's potential as a biomarker. Methods: Consecutive PAH patients diagnosed via right-heart catheterization at Malatya Turgut Ozal E & gbreve;itim ve Ara & scedil;t & imath;rma Hastanesi (Dec 2022 - Apr 2024) were enrolled. Patients were classified into low-risk and high-risk groups based on comprehensive risk assessments that included clinical parameters, hemodynamic measurements and biomarkers, in-line with ESC/ERS guidelines. Serum IL-34, hs-CRP, and NT-proBNP levels were measured and compared with those of healthy controls. Echocardiographic assessments and statistical analyses, including ROC analysis, were conducted to evaluate biomarker significance and predictive capabilities. Results: The mean age of low-risk and high-risk PAH patients was 42 +/- 7.2 years and 45 +/- 5.5 years, respectively. The mean age of the control group was 40 +/- 6.4 years. Males comprised 54.29 % of the low-risk group, 56 % of the high-risk group, and 53.3 % of the control group. IL-34 and hs-CRP levels were significantly elevated in PAH patients compared to controls. IL-34 correlated positively with systolic pulmonary artery pressure, RA area, and NT-proBNP levels. Multivariate analysis revealed that IL-34 and hs-CRP were independent predictors of PAH. IL-34 levels>29.8 pg/mL predicted PAH with 78 % sensitivity and 69 % specificity, while levels >44.4 pg/mL predicted high-risk PAH with 84 % sensitivity and 77 % specificity. Conclusion: Elevated IL-34 and hs-CRP levels are associated with PAH severity and right ventricular dysfunction, suggesting IL-34's potential as a diagnostic and prognostic biomarker. Further research is needed to validate these findings and explore IL-34-targeted therapies in pH management.
引用
收藏
页码:202 / 207
页数:6
相关论文
共 50 条
  • [31] Prognostic role of IL-34 in sepsis and sepsis-induced acute lung injury: preliminary results and future directions
    Cai, Run
    Ren, Jianke
    Zhou, Chenwei
    Liu, Yuxin
    Tang, Jianlei
    Cui, Weiyan
    Yan, Yongmin
    Xue, Sheliang
    Zhou, Yanjuan
    ACTA BIOCHIMICA POLONICA, 2025, 72
  • [32] Angiogenic and inflammatory biomarkers for screening and follow-up in patients with pulmonary arterial hypertension
    Kylhammar, D.
    Hesselstrand, R.
    Nielsen, S.
    Scheele, C.
    Radegran, G.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2018, 47 (04) : 319 - 324
  • [33] An Overview of Circulating Pulmonary Arterial Hypertension Biomarkers
    Santos-Gomes, Joana
    Gandra, Ines
    Adao, Rui
    Perros, Frederic
    Bras-Silva, Carmen
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [34] Circulating Biomarkers in Pulmonary Arterial Hypertension: An Update
    Correale, Michele
    Tricarico, Lucia
    Bevere, Ester Maria Lucia
    Chirivi, Francesco
    Croella, Francesca
    Severino, Paolo
    Mercurio, Valentina
    Magri, Damiano
    Dini, Frank
    Licordari, Roberto
    Beltrami, Matteo
    Dattilo, Giuseppe
    Salzano, Andrea
    Palazzuoli, Alberto
    BIOMOLECULES, 2024, 14 (05)
  • [35] Clinical perspective: biomarkers in pulmonary arterial hypertension
    Heresi, G. A.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2011, 65 : 5 - 7
  • [36] Hypochloridemia as a Prognostic Marker in Pulmonary Arterial Hypertension
    Kalra, Rajat
    Prins, Kurt
    Rose, Lauren
    Pritzker, Marc
    Thenappan, Thenappan
    CIRCULATION, 2017, 136
  • [37] Prognostic markers for idiopathic pulmonary arterial hypertension
    Guo Xiaomin
    Jin Hongfang
    Du Junbao
    CHINESE MEDICAL JOURNAL, 2014, 127 (21) : 3798 - 3802
  • [38] New prognostic markers in pulmonary arterial hypertension: CRP to albumin ratio and uric acid
    Cerik, Idris Bugra
    Dindas, Ferhat
    Koyun, Emin
    Dereli, Seckin
    Sahin, Anil
    Turgut, Okan Onur
    Gul, Ibrahim
    CLINICAL BIOCHEMISTRY, 2022, 100 : 22 - 28
  • [39] The role of cardiac magnetic resonance imaging in pulmonary arterial hypertension and chronic thrombo-embolic pulmonary hypertension
    Valentin, S.
    Maurac, A.
    Mandry, D.
    Selton-Suty, C.
    Huttin, O.
    Cherifi, A.
    Guillaumot, A.
    Gomez, E.
    Chabot, F.
    Chaouat, A.
    REVUE DES MALADIES RESPIRATOIRES, 2022, 39 (05) : 486 - 497
  • [40] Angiogenic and inflammatory biomarkers in the differentiation of pulmonary hypertension
    Saleby, Joanna
    Bouzina, Habib
    Lundgren, Jakob
    Radegran, Goran
    SCANDINAVIAN CARDIOVASCULAR JOURNAL, 2017, 51 (05) : 261 - 270